TriVascular Technologies prices IPO at $12, below the range

By Renaissance Capital,

Shutterstock photo

TriVascular Technologies, which markets the smallest and most versatile stent grafts for endovascular aortic repair, raised $78 million by offering 6.5 million shares at $12, below the range of $13 to $15. TriVascular Technologies will list on the NASDAQ under the symbol TRIV. The company initially filed confidentially on December 16, 2013. J.P. Morgan and Credit Suisse acted as joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: TRIV

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by